Abstract:Introduction Gastric cancer (GC) is the fourth leading cause of cancer death worldwide. Due to the lack of effective chemotherapy methods for advanced gastric cancer and poor prognosis, the emergence of immunotherapy has brought new hope to gastric cancer. Further research is needed to improve the response rate to immunotherapy and identify the populations with potential benefits of immunotherapy. It is unclear whether m7G-related lncRNAs influence tumour immunity and the prognosis of immunotherapy. Methods This study evaluated 29 types of immune cells and immune functions in gastric cancer patients, and m7G-related lncRNAs and their molecular subtypes were identified. In addition, we also studied the biological function characteristics of m7G-related lncRNA molecular subtypes. Finally, the patient's risk score was calculated based on m7G-related lncRNAs, and a nomogram of staging and risk groups was established to predict the prognosis. For experimental verification, RT–qPCR were preformed from the native cohort. Results After identifying m7G-related lncRNAs and their molecular subtypes, we found three molecular subtypes, the B subtype had the highest level of infiltration, and the B subtype may benefit more from immunotherapy. We divided GC patients into two regulator subtypes based on biological function. The two subtypes have significant immunological differences and can be used to judge ICI treatment. We established a risk score formula based on five lncRNAs, including LINC00924, LINC00944, LINC00865, LINC00702, and ZFAS1. Patients with poor prognoses were closely related to patients in the high-risk group. After comprehensive analysis of different risk groups, the efficacy of the high-risk group on bleomycin, cisplatin, docetaxel, doxorubicin and etoposide was better than that of the low-risk group, suggesting that risk subgroups based on risk scores play a guiding role in chemotherapy and that the high-risk group may benefit more from immunotherapy. RT–qPCR results showed that LINC00924, LINC00944, and LINC00865 were highly expressed in tumour tissues, while LINC00702 and ZFAS1 were expressed at low levels in tumour tissues. Discussion In conclusion, we were the first to discover that m7G-related lncRNAs play a vital role in the tumour immune microenvironment of gastric cancer, and a risk prediction model was established to identify patients with potential benefits from immunotherapy and predict the prognosis of GC patients.

Immune perturbation network identifies an EMT subtype with chromosomal instability and tumor immune-desert microenvironment

Immune landscape of advanced gastric cancer tumor microenvironment identifies immunotherapeutic relevant gene signature

Identification of Tumor Mutation Burden, Microsatellite Instability, and Somatic Copy Number Alteration Derived Nine Gene Signatures to Predict Clinical Outcomes in STAD.

Classification of Gastric Cancers Based on Immunogenomic Profiling.

Identification of molecular patterns and prognostic models of epithelial–mesenchymal transition- and immune-combined index in the gastric cancer

Identification of novel tumor microenvironment-associated genes in gastric cancer based on single-cell RNA-sequencing datasets

Unsupervised Hierarchical Clustering Identifies Immune Gene Subtypes in Gastric Cancer

Immunogenomic Classification of Gastric Cancer Based on the Tumor Microenvironments Expression of PD-L1 and CD8+T-cell Infiltration.

Integrated analysis from multicentre studies identities m7G-related lncRNA-derived molecular subtypes and risk stratification systems for gastric cancer

Molecular Subtypes and CD4+ Memory T Cell-Based Signature Associated With Clinical Outcomes in Gastric Cancer

Construction of molecular subtype and prognostic model for gastric cancer based on nucleus-encoded mitochondrial genes

Correlation Between Tumor Microenvironment and Immune Subtypes Based on CD8 T Cells Enhancing Personalized Therapy of Gastric Cancer

Five EMT‐related Genes Signature Predicts Overall Survival and Immune Environment in Microsatellite Instability‐high Gastric Cancer

Characterization of Immune-Related Molecular Subtypes and a Prognostic Signature Correlating with the Response to Immunotherapy in Patients with Gastric Cancer

Identification of an Immune-Related Signature Predicting Survival Risk and Immune Microenvironment in Gastric Cancer.

Subtyping of gastric cancer based on basement membrane genes that stratifies the prognosis, immune infiltration and therapeutic response

Identification of a 3-Gene Model as Prognostic Biomarker in Patients With Gastric Cancer

Identification and Validation of Tumour Microenvironment-Based Immune Molecular Subgroups for Gastric Cancer: Immunotherapeutic Implications

Identification of prognostic gene expression signatures based on the tumor microenvironment characterization of gastric cancer

Immune signature profiling identified prognostic factors for gastric cancer

Single Cell and Bulk RNA Sequencing Identifies Tumor Microenvironment Subtypes and Chemoresistance-Related IGF1+ Cancer-Associated Fibroblast in Gastric Cancer